Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

July 31, 2024

Study Completion Date

September 30, 2024

Conditions
Iron Deficiency Anemia (IDA)Pregnancy
Interventions
DRUG

Iron Carboxymaltose

In ferrous carboxymaltose treatment maximum dose per sitting was 1000 mg, diluted in 200 ml 0.9% normal saline and administered as an IV infusion over 30 min. Parenteral iron therapy was administered under doctor's supervision. The women were then followed up after 3 weeks of completion of therapy. On follow up, hemoglobin and serum ferritin were measured again.

DRUG

Iron Sucrose Injection

Iron sucrose infusion was administered as 300 mg in 200 ml NS over 15-20 min twice weekly till dosage was completed, not exceeding 600 mg per week. Parenteral iron therapy was administered under doctor's supervision. The women were then followed up after 3 weeks of completion of therapy. On follow up, hemoglobin and serum ferritin were measured again.

Trial Locations (1)

60000

Cmh Multan Institute of Medical Sciences, Multan

All Listed Sponsors
lead

CMH Multan Institute of Medical Sciences

OTHER_GOV

NCT06911034 - Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women | Biotech Hunter | Biotech Hunter